We are live on
!
Find out more
EA
Emerald Advisers Portfolio holdings
AUM
$3.16B
1-Year Est. Return
109.58%
This Fund
S&P 500
This Quarter
Est. Return
+16.33%
1 Year Est. Return
+109.58%
3 Year Est. Return
+352.93%
5 Year Est. Return
+451.34%
10 Year Est. Return
+3,577.15%
AUM
$2.37B
AUM Growth
+$227M
(+11%)
Cap. Flow
-$5.81M
Cap. Flow
% of AUM
-0.25%
Top 10 Holdings %
Top 10 Hldgs %
19.78%
Holding
359
New
114
Increased
58
Reduced
128
Closed
21
Top Buys
| 1 |
BellRing Brands
BRBR
|
+$32M |
| 2 |
QTS
QTS REALTY TRUST, INC.
QTS
|
+$18M |
| 3 |
PRFT
Perficient Inc
PRFT
|
+$15.7M |
| 4 |
Axos Financial
AX
|
+$14.4M |
| 5 |
Ameris Bancorp
ABCB
|
+$13.4M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$33M |
| 2 |
CADE
Cadence Bancorporation
CADE
|
+$29.6M |
| 3 |
VG
Vonage Holdings Corporation
VG
|
+$15.7M |
| 4 |
ARQL
Arqule Inc
ARQL
|
+$15.6M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$14.4M |
Sector Composition
| 1 | Healthcare | 21.26% |
| 2 | Consumer Discretionary | 16.72% |
| 3 | Industrials | 15.68% |
| 4 | Technology | 14.21% |
| 5 | Consumer Staples | 9.17% |
Similar funds
AWE
FTUS
BFA
BP
CVA
DWP
GKWIM
BI
Emerald Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, Emerald Advisers held 359 positions worth $2.37B, up 11% from $2.14B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Emerald Advisers's Q4 2019 filing shows 114 new, 58 increased, 128 reduced and 21 closed positions. Its largest new stake was BellRing Brands: 1,634,376 shares worth $34.8M. The largest sale was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $33M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Industrials.
- Emerald Advisers's largest Q4 2019 buy was BellRing Brands: 1,634,376 shares worth $34.8M.
- Emerald Advisers added most to Perficient Inc in Q4 2019, an estimated $15.7M increase.
- Emerald Advisers's biggest Q4 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $33M.
- Emerald Advisers fully exited Arena Pharmaceuticals Inc in Q4 2019, selling an estimated $13.2M.
- Emerald Advisers's ten largest holdings make up 20% of its $2.37B portfolio in Q4 2019.
- Emerald Advisers opened 114 new positions and closed 21 in Q4 2019.
- Emerald Advisers's portfolio value rose 11% quarter-over-quarter to $2.37B.
Based on Emerald Advisers's 13F filing for Q4 2019, filed 29 Jan 2020.